WuXi Genuo announced at the 63rd Annual Meeting of the American Society of Hematology (ASH) the main clinical application of Benoda® (Rigiolense Injection) for the treatment of relapsed/refractory follicular lymphoma in Chinese adult patients Effect

Shanghai, December 13, 2021/PRNewswire/ - WuXi Juno (HKEx code: 2126), an independent and innovative biotechnology company focusing on the development, production and commercialization of cellular immunotherapy products, in At the 63rd Annual Meeting of the American Society of Hematology (ASH), the main clinical effects of Benoda® (Rigiolense Injection) for the treatment of relapsed/refractory follicular lymphoma in Chinese adult patients were announced

As of the data deadline September 10, 2021, a total of 28 Chinese adult patients with relapsed/refractory follicular lymphoma received Benoda® treatment and reached a follow-up period of at least three months

Among the 27 patients with evaluable effectiveness, the best objective response rate (ORR) based on the investigator's assessment was 100% (27/27), and the best complete response rate (CRR) was 92.

Among 28 patients treated with Benoda®, the incidence of all grades and severe (≥3 grade) cytokine release syndrome (CRS) was 42.

Dr.

Reference materials:

Song, Y.

About Benoda® (Rigid Orense Injection)

Benoda ® (Rigid Orenza Injection) is a self-developed CD19-targeted CD19 based on the CAR-T cell process platform of Junuo Medical (a Bristol-Myers Squibb company).

About WuXi Giant Nuo

WuXi Giant Nuo (HKEx code: 2126) is an independent and innovative biotechnology company focusing on the development, production and commercialization of cellular immunotherapy products

Forward-looking statement

The forward-looking statements contained in this release are based on management’s current expectations and confidence, and there are certain uncertainties or risks that may cause actual results to be substantially different from those described

Source: WuXi Giant Nuo